Category

Archives

Immunology & Inflammation related

β-escin activates ALDH and prevents cigarette smoke-induced cell death

57 views | Feb 05 2024

β-escin demonstrates promising potential as a cytoprotective agent against cigarette smoke-induced damage in nasal epithelial cells by enhancing ALDH activity and mRNA expression of ALDH isoforms. [Read the Full Post]

Combination of AS101 and Mefloquine Inhibits Carbapenem-Resistant Pseudomonas aeruginosa in vitro and in vivo

74 views | Jan 05 2024

The synergistic combination of AS101 and mefloquine exhibits potent antibacterial effects against carbapenem-resistant Pseudomonas aeruginosa, demonstrating promising potential for future clinical applications in treating CRPA infections. [Read the Full Post]

Bestatin, A Pluripotent Immunomodulatory Small Molecule, Drives Robust and Long-Lasting Immune Responses as an Adjuvant in Viral Vaccines

55 views | Jan 03 2024

The inclusion of bestatin as an adjuvant in inactivated foot-and-mouth disease vaccines significantly enhances immune response in experimental animals, showcasing its potential to improve vaccine efficacy and induce long-lasting immunity. [Read the Full Post]

C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2α-ATF4-CREB3L1 pathway

86 views | Dec 30 2023

High levels of C5a accelerate vascular smooth muscle cell calcification via C5aR1, activating the PERK-eIF2α-ATF4-CREB3L1 pathway, highlighting C5 or C5aR1 as potential therapeutic targets for vascular calcification. [Read the Full Post]

CD97 negatively regulates the innate immune response against RNA viruses by promoting RNF125-mediated RIG-I degradation

50 views | Dec 26 2023

The study reveals that the G protein-coupled receptor CD97 acts as a negative regulator of the antiviral immune response by promoting RIG-I degradation, suppressing IFN-I signaling, and offers potential for targeted antiviral therapies through inhibition of CD97. [Read the Full Post]

Hydrogen Sulfide Improves Outcomes in a Murine Model of Necrotizing Enterocolitis via the Cys440 Residue on Endothelial Nitric Oxide Synthase

171 views | Nov 17 2023

GYY4137 administration improves clinical outcomes, attenuates intestinal and lung injury, and enhances perfusion in a murine model of necrotizing enterocolitis, with these protective effects being contingent upon the presence of the Cys440 residue in endothelial nitric oxide synthase (eNOS). [Read the Full Post]

Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy

42 views | Nov 02 2023

This study demonstrates that ultrasound-derived measures of tumor stiffness and perfusion can serve as predictive biomarkers for the efficacy of immune checkpoint inhibition in cancer patients, providing valuable insights into the tumor microenvironment and aiding in the development of personalized treatment strategies. [Read the Full Post]

HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy

69 views | Oct 03 2023

The evolving understanding of HDL's complex functions beyond its cholesterol content, including its role in reverse cholesterol transport, suppression of inflammatory signaling, and protection against oxidative modifications, has led to the realization that HDL-C levels alone do not necessarily reflect HDL function in atherosclerotic cardiovascular disease (ASCVD). [Read the Full Post]

[Decursin affects proliferation, apoptosis, and migration of colorectal cancer cells through PI3K/Akt signaling pathway]

42 views | Sep 15 2023

Decursin inhibits proliferation, induces apoptosis, suppresses migration, and regulates epithelial-mesenchymal transition in colorectal cancer cells through downregulation of the PI3K/Akt pathway and modulation of key proteins involved in cell survival, apoptosis, and cell-cell adhesion. [Read the Full Post]

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

98 views | Aug 24 2023

The phase 1 study demonstrated that hepatic impairment had no clinically significant impact on the pharmacokinetics of iberdomide, supporting the conclusion that no dose adjustment is necessary for patients with hepatic impairment. [Read the Full Post]